MDNA Life Sciences Inc. (MDLS)
MDNA Life Sciences is a life sciences company focused on the development of liquid biopsy tests based on the mitochondrial genome.
We have discovered novel biomarkers and designed laboratory assays, which we refer to as our Mitomic Technology, that are intended to use mitochondrial DNA to detect cancer earlier, more accurately, and less invasively than traditional methods.
Though we have no commercially available FDA or foreign regulator approved products, we have licensed our intellectual property related to the Mitomic prostate cancer biomarker through a license and distribution agreement with Laboratory Corporation of America Holdings, a national US commercial Clinical Laboratory Improvement Amendments lab.
We also have licensed distribution rights through various agreements with international business partners to commercialize our Mitomic Technology, should Mitomic tests be successfully developed and successfully approved by the FDA or a foreign regulator.
We continue to invest in R&D and currently have a robust new product development roadmap focused on proactively addressing emerging customer demands.
We have a specific focus on women’s health initiatives, with a test for endometriosis currently in development and plans to develop tests for ovarian cancer and breast cancer.
We intend to pursue products covering potentially large markets including lung cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, and colorectal cancer.
|Industry||Diagnostics & Research|
|CEO||Christopher C. Mitton|
2054 Vista Parkway, Suite 400
West Palm Beach, FL 33411
|Fiscal Year||October - September|
|Christopher C. Mitton||Chief Executive Officer|
|Jonathan Mills||Chief Financial Officer|
|Jennifer Creed||Chief Development Officer|
|Andrew Harbottle, Ph.D.||Chief Science Officer|
|Robert Poulter||Chief Business Officer|
|Harry Smart||Chairman of the Board of Directors|
|Robert Thayer, Ph.D.||Director|